Depletion of alloreactive T cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity

Blood

Volumn 93, Issue 10, 1999, Pages 3550-3557

  Montagna, Daniela ^a   Yvon, Eric ^b   Calcaterra, Valeria ^b   Comoli, Patrizia ^b   Locatelli, Franco ^b   Maccario, Rita ^b   Fisher, Alain ^b   Cavazzana Calvo, Marina ^b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOTOXIN; INTERLEUKIN 2 RECEPTOR; PROTEIN P55;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIVIRAL ACTIVITY; ARTICLE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HLA SYSTEM; HUMAN; HUMAN CELL; MIXED LYMPHOCYTE CULTURE; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 0033562349     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.10.3550.410k24_3550_3557     Document Type: Article

References (49)

1. Fischer A, Landais P, Friedrich W, Gerritsen B, Blanche S, Fasth A, Porta F, Vellodi A, Benkerrou M, Jais JP, Cavazzana-Calvo M, Souillet G, Bordigoni P, Morgan G, Van Dijken P, Vossen J, Locatelli F, Di Bartolomeo P: Bone marrow transplantation in Europe for primary immunodeficiencies other than severe combined immunodeficiency, EBMT/EGID report. Blood 83:1149, 1994
2. Ash RC, Casper JT, Chitambar CR, Hansen R, Bunin N, Truitt R, Lauton P, Murray K, Hunter J, Baxter-Lowe LA, Gottschall J, Oldham K, Anderson T, Camitta B, Menitove J: Successful allogeneic transplantation of T-cell depleted bone marrow from closely HLA-matched unrelated donors. N Engl J Med 8:485, 1990
3. Henslee-Downey PJ, Abhyankar SH, Parrish RS, Pati AR, Godder KT, Neglia WJ, Goon-Johnson KS, Geier SS, Lee CG, Gee AP: Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood 89:3864, 1997
4. O'Reilly RJ, Keever CA, Small TN, Brochstein J: The use of HLA-non-identical T-cell depleted marrow transplants for correction of severe combined immunodeficiency disease. Immunodeficiency Rev 1:273, 1989
5. Aversa F, Tabilio A, Terenzi A, Velardi A, Falzetti F, Giannoni C, Iacucci R, Zei T, Martelli MP, Gambelunghe C, Rossetti M, Caputo PF, Latini P, Aristei C, Raymondi C, Reisner Y, Martelli MF: Successful engraftment of T-cell-depleted haploidentical "three loci" incompatible transplants in leukemia patients by adding recombinant human granulocyte colony stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 84:3948, 1994
6. Hale G, Waldmann H: Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection. Bone Marrow Transplant 17:305, 1996
7. Jabado N, Le Deist F, Cant A, De Graeff G, Meeders ER, Fasth A, Morgan G, Vellodi A, Hale G, Bujan W, Thomas C, Cavazzana-Calvo M, Widijenes J, Fischer A: Bone marrow transplantation from genetically HLA-non identical donors in children with fatal inherited disorders excluding severe combined immunodeficiencies: Use of two monoclonal antibodies to prevent graft-rejection. Pediatrics 98:420, 1996
8. Cavazzana-Calvo M, Bordigoni P, Michel G, Esperou H, Souillet G, Leblanc T, Stephan JL, Vannier JP, Mechinaud F, Reiffers J, Vilmer E, Landman-Parker J, Benkerrou M, Baruchel A, Pico J, Bernaudin F, Bergeron C, Plouvier E, Thomas C, Widjienes J, Lacour B, Blanche S, Fischer A: A phase II trial of partially incompatible bone marrow transplantation for high-risk acute lymphoblastic leukaemia in children: Prevention of graft rejection with anti-LFA-1 and anti-CD2 antibodies. Br J Haematol 93:131, 1996
9. Haddad E, Landais P, Friedrich W, Gerritsen B, Cavazzana-Calvo M, Morgan G, Bertrand Y, Fasth A, Porta F, Cant A, Espanol T, Müller S, Veys P, Vossen J, Fischer A: Long term immune reconstitution and outcome after HLA-non identical T-cell depleted bone marrow transplantation for severe combined immunodeficiency: A European retrospective study of 116 patients. Blood 91:3646, 1998
10. Cavazzana-Calvo M, Bensoussan D, Jabado N, Haddad E, Yvon E, Moskwa M, Tachet-Descombes A, Buisson M, Morand P, Virion JM, Le Deist F, Fischer A: Prevention of EBV induced B-lymphoproliferative disorder by ex vivo marrow B-cell depletion in HLA phenoidentical or non identical T-depleted bone marrow transplantation. Br J Haematol 103:543, 1998
11. Gribben JG, Guinan EC, Boussiotis VA, Ke XY, Linsley L, Sieff C, Gray GS, Freeman GJ, Nadler LM: Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy: A method to ameliorate graft-versus-host disease and extend the donor pool. Blood 87:4887, 1996
12. Comoli P, Locatelli F, Montagna D, Calcaterra V, Moretta A, Giorgiani G, Bonetti F, Zecca M, Maccario R: Induction of alloantigen-specific anergy does not impair cytolytic activity of leukemia-reactive human T cells. Bone Marrow Transplant 21:5132, 1998 (suppl 1)
13. Mavroudis DA, Jiang YZ, Hensel N, Lewalle P, Cocoriel D, Kreitman RJ, Pastan I, Barrett AJ: Specific depletion of alloreactivity against haplotype mismatched related individuals by a recombinant immunotoxin: A new approach to graft-versus-host disease prophylaxis in haploidentical bone marrow transplantation. Bone Marrow Transplant 17:793, 1996
14. Cavazzana-Calvo M, Fromont C, Le Deist F, Lusardi M, Coulombel L, Derocq JM, Gerota I, Griscelli C, Fischer A: Specific elimination of alloreactive T cells by an anti-interleukin-2 receptor B chain-specific immunotoxin. Transplantation 50:1, 1990
15. Mickey B, Kohn C, Lowdell MW, Prentice HG: Selective removal of alloreactive lymphocytes from peripheral blood mono-nuclear cell preparations. Blood 88:253a, 1996 (suppl 1)
16. Reucher SD, Houston JA, Lockey TD, Hurwitz JL: Eliminating graft-versus-host potential from T cell immunotherapeutic populations. Bone Marrow Transplant 18:415, 1996
17. Valteau-Couanet D, Cavazzana-Calvo M, Le Deist F, Fromont C, Fisher A: Functional study of residual T lymphocytes after specific elimination of alloreactive T cells by a specific anti-interleukin-2 receptor B chain immunotoxin. Transplantation 56:1574, 1993
18. Cavazzana-Calvo M, Stephan JL, Samacki S, Chevret S, Fromont C, de Coene C, Le Deist F, Guy-Grand D, Fisher A: Attenuation of graft-versus-host disease and graft rejection by ex vivo immunotoxin elimination of alloreactive T cells in an H-2 haplotype disparate mouse combination. Blood 83:288, 1994
19. Mavroudis DA, Dermime S, Molldrem J, Jiang YZ, Raptis A, van Rhee F, Hensel N, Felllowes V, Eliopoulos G, Barrett AJ: Specific depletion of alloreactive T cells in HLA-identical siblings: A method for separating graft-versus-host and graft-versus-leukemia reactions. Br J Haematol 101:565, 1998
20. Weiden PL, Flournoy N, Thomas ED, Prentige R, Fefer A, Buckner D, Storb R: Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 300:1068, 1979
21. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringden O, Rozman C, Speck B, Truit RL, Zwaan FE, Bortin MM: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555, 1990
22. Marmont AM, Horowitz MM, Gale RP, Sobocinski K, Ash RC, van Bekkum DW, Champlin RE, Dicke KA, Goldman JM, Good RA, Herzig RH, Hong R, Masaoka T, Rimm AA, Ringden O, Speck B, Weiner RS, Bortin MM: T-cell depletion of HLA-identical transplants in leukemia. Blood 78:2120, 1991
23. Montagna D, Aricò M, Montini E, De Benedetti F, Maccario R: Identification of HLA-unrestricted CD8+/CD28-cytotoxic T cell clones specific for leukemic blasts in children with acute leukemia. Cancer Res 55:3835, 1995
24. Montagna D, Locatelli F, Calcaterra V, Comoli P, Moretta A, Giorgiani G, Zecca M, Bonetti F, Giraldi E, Rondini G, Maccario R: Does the emergence and persistence of donor derived leukemia-reactive cytotoxic T-lymphocytes protect patients given an allogeneic BMT from recurrence? Results of a preliminary study. Bone Marrow Transplant 22:743, 1998
25. Engert A, Martin G, Amlot P, Wijdenes J, Diehl J, Thorpe P: Immunotoxins constructed with anti-CD25 monoclonal antibodies and deglycosylated ricin A-chain have potent anti-tumour effects against human Hodgkin cells in vitro and solid Hodgkin tumours in mice. Int J Cancer 94:450, 1991
26. Bell KD, Ramilo O, Vitetta ES: Combined use of an immunotoxin and cyclosporine to prevent both activated and quiescent peripheral blood T cells from producing type 1 human immunodeficiency virus. Proc Natl Acad Sci USA 90:1411, 1993
27. Winkler U, Gottstein C, Schön G, Kapp U, Wolf J, Hansmann ML, Bohlen H, Thorpe P, Diehl V, Engert A: Successful treatment of disseminated human Hodgkin's disease in SCID mice with deglycosylated ricin A-chain immunotoxins. Blood 83:466, 1994
28. Engert A, Diehl V, Schnell R, Radszuhn A, Hatwig MT, Drillich S, Schön G, Bohlen H, Tesch H, Hansmann ML, Barth S, Schindler J, Ghetie V, Uhr J, Vitetta E: A phase-1 study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma. Blood 89:403, 1997
29. Thorpe PE, Wallace M, Knowles PP, Reif MG, Brown ANF, Watson GJ, Knyba R, Wawrzynczak EJ, Blakey DC: New XXX agents for the synthesis of immunotoxins containing a kindered disulfide bond with improved stability in vivo. Cancer Res 47:5924, 1987
30. Ghetie V, Thorpe PE, Ghetie MA, Knowles P, Uhr JW, Vitetta ES: The GLP large scale preparation of immunotoxins containing deglycosylated ricin A chain and hindered disulfide bond. J Immunol Methods 142:223, 1991
31. McLaughlin-Taylor E, Pande E, Forman SJ, Tanamachi B, Li C, Zaia JA, Greenberg PD, Riddell SR: Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes. J Med Virol 43:103, 1994
32. Moretta A, Comoli P, Montagna D, Gasparoni A, Percivalle E, Carena I, Revello MG, Gerna G, Mingrat G, Locatelli F, Rondini G, Maccario R: High frequency of Epstein-Barr virus (EBV) lymphoblastoid cell line-reactive lymphocytes in cord blood: Evaluation of cytolytic activity and IL-2 production. Clin Exp Immunol 312:107, 1997
33. Sharrock CEM, Kaminski E, Man E: Limiting dilution analysis of human T cells: A useful clinical tool. Immunol Today 11:281, 1990
34. Abrignani S, Montagna D, Jeannet M, Wintsch J, Haigwood NL, Shuster JR, Steimer KS, Cruchaud A, Staehelin T: Priming of CD4+ T cells specific for conserved regions of human immunodeficiency virus glycoprotein gp 120 in human immunized with a recombinant envelope protein. Proc Natl Acad Sci USA 87:6136, 1990
35. Falkenburg JHF, Smit WM, Willemze R: Cytotoxic T-lymphocyte (CTL) responses against acute or chronic myeloid leukemia. Immunol Rev 157:223, 1997
36. Goulmy E: Human minor histocompatibility antigens: New concepts for marrow transplantation and adoptive immunotherapy. Immunol Rev 157:125, 1997
37. Faber LM, van der Hoeven J, Goulmy E, Hooftman-den Otter AL, van Luxemburg-Heijs SAP, Willemze R, Falkenburg JHF: Recognition of clonogenic leukemic cells, remission bone marrow and HLA identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes. J Clin Invest 96:877, 1995
38. + cytotoxic T-lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: Implications for graft-versus-leukemia reactivity. Blood 86:2821, 1995
39. Weiss L, Lubin I, Factorowich I, Lapidot Z, Reich Y, Reisner Y, Slavin S: Effective graft-versus-leukemia effect independent of graft-versus-host disease after T cell depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. J Immunol 153:2562, 1994
40. Jiang JYZ, Mavroudis DA, Dermine S, Molldrem J, Hensel NF, Barrett AJ: Preferential usage of T cell receptor (TCR) V by allogeneic T cells recognizing myeloid leukemia cells: Implications for separating graft-versus-leukemia effect from graft-versus-host disease. Bone Marrow Transplant 19:899, 1997
41. Slavin S, Ackerstein A, Naparstek E, Or R, Weiss L: The graft-versus-leukemia (GVL) phenomenon: Is GVL separable from GVHD? Bone Marrow Transplant 6:155, 1990
42. van Lochem E, de Gast B, Goulmy E: In vitro separation of host specific graft-versus-host and graft-versus-leukemia cytotoxic T cell activities. Bone Marrow Transplant 10:181, 1992
43. Guinan EC, Gribben JG, Boussiotis VA, Freeman GJ, Nadler LM: Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood 84:3261, 1994
44. + T-cell line with potent in vivo graft-versus-leukemia properties. Blood 89:3477, 1997
45. Lenschow DJ, Walunas TL, Bluestone JA: CD28/B7 system of T cell costimulation. Annu Rev Imunol 14:233, 1996
46. Zocchi MR, Ferrarini M, Rugarli C: Selective lysis of the autologous tumor by TCS1+ tumor infiltrating lymphocytes from human lung carcinoma. Eur J Immunol 20:2685, 1990
47. Douval M, Yotnda P, Benussan A, Oudhri N, Guidai C, Rohrlich P, Boumsel L, Grandchamp B, Vilmer E: Potential antileukemic effect of γδ T cells in acute lymphoblastic leukemia. Leukemia 9:863, 1995
48. Ashwell JD, Chen C, Schwartz RH: High frequency and nonrandom distribution of alloreactivity in T cell clones selected for recognition of foreign antigen in association with self class II molecules. J Immunol 136:389, 1986
49. Matzinger P: Tolerance, danger, and the extended family. Annu Rev Immunol 12:991, 1994